The binding of AGPG to PURα resulted in the dissociation of PURα from the PURα/E2F1 complex, which dampened the effect of PURα on the activation of the E2F1 signaling pathway, and intensified the endocrine resistance of BC cells. Here, E2F1 is linked to breast cancer.